I'd feel better if the climate for financing was easier. They hinted broadly in the last CC that they had projects worth pursuing that were being held back because they considered it necessary to stay GAAP profitable.
It was amusing that with the corporate pitch being that Volcano products make stenting more cost-effective, the stock got whacked along with the stent makers when there was a news story about push-back against excessive use of medical devices.